PRISM BioLab (206A) · FactRestatedLatest Other Disclosures (2026-05-08): "Advanced"
Building an intracellular PPI drug discovery platform using PepMetics
First written in FY2024. 1 of 3 entries say "Restated". Latest entry: 2026-05-08.
3entries
3years
1from disclosures
How it moved
Same theme, other companies
PepMetics Intracellular PPI Drug Discovery PlatformA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-05-08AdvancedOther Disclosures
「This allowance is based on a new molecular scaffold covering our library compound group, in connection with the “Notice of PRISM BioLab’s Acquisition of Patents for PepMetics® Technology Library Compounds” disclosed by the company on 9 June 2025.」
The disclosure showed that a US patent application covering the PepMetics technology library compound group received a notice of allowance based on a new molecular scaffold, recording progress in the intellectual property supporting the technology platform. - FY2025RestatedAnnual report
「PepMetics technology controls intracellular protein-protein interactions (PPI) using small-molecule organic compounds that mimic helical structures.」
The company has reiterated its drug discovery platform for controlling intracellular PPIs with helix-mimetic small molecules, and described its applications in libraries, HTS, computational chemistry, and biophysics. - FY2024First statedAnnual report
「PepMetics technology controls intracellular protein-protein interactions (PPI) using small-molecule organic compounds that mimic helical structures.」
The company also describes the specific components of its technology platform, including more than 40 scaffolds, more than 50 side chains, and more than 20,000 physical libraries.